Therapeutic cancer vaccines: Navigating clinical translation and multimodal synergy
-
By
-
Chu, Tan-Huy
-
Huynh, Thuy Linh
-
Phuong, Le-Tri
-
April 13, 2026
-
Clinical Scorecard: Cancer Vaccines as Therapy: Challenges in Clinical Application and Multimodal Integration
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Induction of robust T cell responses against malignant cells, including epitope spreading and antigen selection. |
| Target Population | |
| Care Setting | |
Key Highlights
- Therapeutic cancer vaccines (TCVs) can induce enduring T cell responses.
- Current clinical efficacy of TCVs is limited by various challenges.
- Combination strategies are being explored to enhance TCV effectiveness, including specific therapies.
- Manufacturing obstacles and immunosuppressive tumor microenvironment hinder outcomes.
- Rational therapeutic strategies and refined patient selection are crucial for success.
Guideline-Based Recommendations
Diagnosis
Management
- Consider multimodal integration of TCVs with other therapies, such as checkpoint inhibitors or chemotherapy.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Cancer patients, especially those with minimal residual disease.
TCVs may improve outcomes when combined with other therapeutic strategies.
Clinical Best Practices
- Implement rational therapeutic strategies to overcome manufacturing challenges.
- Focus on patient selection to maximize TCV efficacy.
- Monitor the tumor microenvironment and patient response to tailor treatment approaches.
Related Resources & Content
